A single center, retrospective cohort study assessing the safety and efficacy of Venetoclax with either Decitabine or Azacitidine compared to alternative therapies in relapsed and refractory Acute Myeloid Leukemia
Latest Information Update: 10 Jan 2021
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cytarabine; Decitabine; Enasidenib; Fludarabine; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology